Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPAS study in patients with cystic fibrosis
NL-OMON27235Recruiting
- Sponsor
- Erasmus MC
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa airway infection (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in FEF75 after 4 weeks of targeted treatment. Started May 2015; status: recruiting.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa airway infection
Beyond the preview
Go deeper on NL-OMON27235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27235.